Online inquiry

IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15688MR)

This product GTTS-WQ15688MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets VEGFA gene. The antibody can be applied in Macular edema following Central Retinal Vein Occlusion (CRVO), Diabetic retinopathy research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7422
UniProt ID P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ15688MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6449MR IVTScrip™ mRNA-Anti-HA, CT-P23(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CT-P23
GTTS-WQ15062MR IVTScrip™ mRNA-Anti-KDR, SSS-23(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SSS-23
GTTS-WQ1437MR IVTScrip™ mRNA-Anti-Aβ15-42, ACC-001(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ACC-001
GTTS-WQ12069MR IVTScrip™ mRNA-Anti-CD19, MOR-00208(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MOR-00208
GTTS-WQ14832MR IVTScrip™ mRNA-Anti-CD70, SGN-75(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-75
GTTS-WQ4928MR IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA C11D5.3 scFv-8A-F9Z CAR
GTTS-WQ2913MR IVTScrip™ mRNA-Anti-IL17RA, AMG827(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG827
GTTS-WQ12594MR IVTScrip™ mRNA-Anti-F11, NVS250519(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA NVS250519
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW